INTRODUCTION
Continuous ambulatory peritoneal dialysis (CAPD) was introduced in 19761 and soon became one of the most popular modes of home dialysis. There is no single qualitative or quantitative index by which to evaluate the efficacy of CAPD. This paper will present evidence to suggest that CAPD provides adequate dialysis according to the following criteria: 1 ) It sustains life in patients with end-stage renal disease (ESRD).
2) It maintains patients in a satisfactory condition while awaiting a kidney transplant, and it does not adversely affect the results of transplantation; if the latter fails, CAPD can be recommenced after transplant nephrectomy.
3) It provides a satisfactory quality of life as indicated by adequate rehabilitation and sexual activity. 4) It can sustain children, and facilitate their growth. 5) It can provide adequate biochemical control. 6) It can arrest or even ameliorate uraemic complications. Furthermore, it is an inexpensive process. In addition the adequacy of CAPD will be demonstrated by comparing its results with those of the more firmly established dialysis modality -chronic haemodialysis.
Continuous ambulatory peritoneal dialysis (2) S49 SURVIVAL ON CAPD In Toronto Western Hospital, survival at the end of 1, 2, 3, 4, 5 years is 90%, 80 %, 70%, 65 % and 46 % respectively (Fig 1) . The attrition rate is about 10% per year. Data concerning the various forms of dialysis used in Canada in shows that the non-diabetic CAPD patients (n = 596), who were, on average, 4 years older than those on haemodialysis, have a 90% and 80% chance of survival at the end of 12 and 24 months respectively. During this same period, the non-diabetics on haemodialysis (n = 1 161) had a survival rate of 85% and 75 %. At the end of two years, the probability of dropout (failures and deaths together) was 48 % on CAPD, and 41 % on haemodialysis. Thus by these criteria the two modalities were comparable. The European Dialysis and Transplant Association (EDTA) studied a large number of CAPD patients and compared them with patients on other replacement therapies.3 They had 3607 patients registered on CAPD by the end of December 1982. Their data showed that the survival of CAPD patients in various age groups is comparable with that on other modalities (Tables la and lb) . In all age groups, survival of diabetics on CAPD at one year was consistently better than that of the general diabetic population on renal replacement therapy, although no statistical analysis was provided. 34  97  93  93  35 -44  96  90  91  45 -54  90  92  84  90  55 -64  84  77  85  65  75  77  76 (1) Value extracted from a figure.
(2) Irrespective of any subsequent changes in the mode of treatment. QUALITY OF LIFE It is difficult to measure quality of life. Sometimes it can only be inferred from the patient's activity level, employment status, sexual activity and relationship with the other family members. A review of the level of rehabilitation among the patients in our programme at the end of 1983 (Table 11 ), showed that 38% were working full-time -either in employment or as homemakers with normal activity. The level of the rehabilitation in work scale is low because a large proportion of our patients were over the retirement age; this result is not significantly different from that reported for a large population of ESRD patients on haemodialysis.9 Fifty-four per cent of our patients claimed that their daily activity was normal. Among the 59 young (2) Cognitive function A large proportion of patients with advanced renal failure have a significant degree of cognitive dysfunction which is attributed to neurotoxicity before treatment. Kenny43 developed an 'impairment index' to assess cognitive dysfunction in individual CAPD patients. This index, which ranges from 0.0 (no impairment) to 1.0 (severe impairment), is calculated on the basis of eight psychometric tests. He studied 46 patients over 12 months of CAPD treatment. In the beginning, only 37 % of them had normal cognitive function (score 0.0-0.2), whereas 22.7 % had markedly impaired function (score > 5.0). At the end of one year, 59% had normal cognitive function and the proportion of those with markedly impaired scores dropped to 13%. The population of non-impaired patients increases up to 70 % after treatment for two years or more. Renal osteodystrophy Renal osteodystrophy is a major complication of long-term dialysis. With the better control of serum phosphorus, one would expect improvement in the course of renal osteodystrophy in CAPD patients. So far the results have been conflicting. Tielemans et al44 found that osteitis fibrosa progressed in 15 patients who were on CAPD for 7 to 28 months. Teitelbaum et al45 studied six CAPD patients by repeated bone biopsies and found that osteomalacia improved whereas the osteitis fibrosa worsened. Gokal et al46 studied 40 CAPD patients dialysed with a dialysate calcium of 7 mg/dl and found improvement of both osteomalacia and osteitis fibrosa during the first year. The parathyroid hormone level declined in three-quarters of the patients. Digenis et al47 reviewed the radiological evidence of renal osteodystrophy in 27 patients who had been on CAPD for three years or more. According to the radiological findings at the beginning of the treatment, they divided these 27 patients (10 males and 17 females) into two groups: Group A (10 patients) included those who had no subperiosteal resorption, and group B (17 patients) those with increased subperiosteal resorption. In group A, the radiological findings remained normal in 8 and progressed in 2. In group B, subperiosteal resorption remained unchanged or progressed in 14, while it improved in the other 3. Plasma PTH levels paralleled the radiological changes. Of the 27, 7 developed spontaneous fractures which, however, healed with callus formation. Thus secondary hyperparathyroidism persists in patients on long-term CAPD in our experience; this may be due to a low dialysate calcium and low oral calcium intake. Abnormalities in lipid metabolism Almost one-half of those on CAPD develop hypertriglyceridaemia, which has been attributed to the large load of glucose (150 -200 g) absorbed daily from the dialysate. In a prospective study of the effect of three to six months on CAPD48 on serum lipids, we found that patients with high triglycerides before starting CAPD continued to have high levels, which, in some, rose even further. The VLDL cholesterol also increased whereas HDL cholesterol did not change. Serum triglyceride and cholesterol levels remained normal in those who had normal lipid profiles at the start of CAPD. After three to six months of CAPD, the HDL cholesterol increased significantly in this group. Lindholm et al49 also found that the serum lipids remained normal in a large proportion of their CAPD patients.
Hypotension and peripheral vascular disease CAPD controls blood pressure so effectively that occasionally these patients develop orthostatic hypotension. Brown et al50 reported that a drop in the systemic blood pressure and in the already impaired perfusion of the ischemic limbs could exacerbate symptoms of peripheral vascular disease. It may be necessary to remove patients from CAPD and allow their blood pressure to increase so as to alleviate the symptoms of peripheral vascular disease. Leenen et a151 studied 5 symptomatic, hypotensive patients before and after oral salt loading, during which they did not allow a concomitant increase of body weight. The patients received between 85 and 170 mmol of sodium per day in addition to the original daily intake. Salt-loading lasted two to three weeks. Supine blood pressure increased markedly after salt loading, from 94/67 mmHg to 121/78 mmHg, and the symptoms of orthostatic hypotension disappeared. Salt-loading appears to confer its benefits by increasing extracellular fluid volume and sympathetic tone, as assessed by plasma norepinephrine levels and the pressor responsiveness to norepinephrine.
Causes of death
Of 257 patients on our CAPD programme, 42 had died. Sixteen died of cardiovascular causes and 10 died suddenly. We believe that most of the latter died of cardiac causes, because most of them had evidence of cardiac abnormalities on routine tests before death and none had electrolyte disturbances. Thus cardlovascular deaths accounted for more than one-half of the deaths on CAPD. Seven patients died of peritonitis. They either had a Staphylococcus aureus infection or faecal peritonitis due to perforation of viscus. The remaining 9 deaths were due to causes such as pancreatitis, withdrawal from dialysis and malignancies.
COMPARISON OF THE COSTS OF THE VARIOUS MODES OF DIALYSIS
The most expensive part of any dialysis therapy is the services of medical personnel and the provision of equipment. CAPD achieves the most effective reduction in labour costs because the patient carries out the entire procedure. This mode requires only minimal equipment. The Toronto ESRD Task Force has calculated that (per patient year) CAPD costs much less than centre peritoneal dialysis and haemodialysis.52 It is also cheaper than home dialysis.52,53 In Toronto (1983) CAPD costs Can $15,000 per patient year compared with Can $27,000 for centre haemodialysis and Can $18,000 for home haemodialysis. Most centres refer patients of advanced age and those with cardiovascular diseases to the CAPD programme because it achieves a stable haemodynamic and biochemical condition. These patients tend to have multiple medical problems and hence to require frequent admissions which invariably add to the total cost of CAPD. Even though CAPD is less expensive than hospital or facility based haemodialysis, it still remains relatively expensive and we should continue our efforts to lower the cost of dialysis solutions -the main expense. We can reduce the cost of CAPD by decreasing the frequency of exchanges from four to three per day, using either 2 or 3 litre bags. This modification would lower the total cost of dialysis solution but also would reduce the cost of peritonitis treatment, because the frequency of peritonitis is much lower in those using three exchanges per day.54 At a time when economic resources are limited, reducing the cost of renal replacement therapy to a minimum will enable physicians to treat more patients with end-stage renal failure.
CONCLUSION
As this paper explains, CAPD provides adequate removal of metabolic wastes, ameliorates some of the common long-term complications and restores disturbed physiology towards normal in end-stage renal failure. Thus CAPD is an important treatment for patients with end-stage renal disease. While it is the treatment of choice for some patients it may not be tolerated by others who then will be maintained by haemodialysis. Centres which cannot provide both haemodialysis and CAPD with equally high standards function under a considerable handicap.
